Shernan G Holtan MD - Allogeneic HCT/ Cell Therapy (She/Her)
Hematologic Oncology
Chief of Blood and Marrow Transplantation, Professor of Medicine
Join to View Full Profile
Elm and CarltonBuffalo, NY 14209
Dr. Holtan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Shernan Holtan is an internationally recognized hematologist based in Buffalo, NY, with specialized expertise in hematologic oncology. After graduating from the University of Nebraska College of Medicine in 2003, she completed both her residency and fellowship training at the Mayo Clinic College of Medicine and Science. Dr. Holtan currently holds the position of Professor of Medicine and Chief of Blood and Marrow Transplantation at Roswell Park Comprehensive Cancer Center. Her groundbreaking work encompasses hematopoietic stem cell transplantation, graft-versus-host disease (GVHD), strength training, and regenerative medicine. Dr. Holtan's leadership in investigator-initiated clinical trials has been transformative, notably her pivotal role as co-leader of BMT CTN 1703, a landmark study published in the New England Journal of Medicine in 2023, which led to the global adoption of post-transplant cyclophosphamide for GVHD prophylaxis. Recognized for her significant clinical and translational contributions, she received the prestigious Lukas Wartman GVHD Achievement Award at the ASTCT/CIBMTR Tandem Meetings in 2025.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2006 - 2010- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2003 - 2006
University of Nebraska College of MedicineClass of 2003
Hastings CollegeBA, Biopsychology, 1998
Certifications & Licensure
NY State Medical License 2023 - 2027
MN State Medical License 2004 - 2026
OR State Medical License 2011 - 2013
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2016-2017
- Red Rose Award Oregon Health & Science University, 2013
Clinical Trials
- MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Start of enrollment: 2014 Jul 10
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
- Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant Start of enrollment: 2020 Oct 29
Publications & Presentations
PubMed
- Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-cel.Megan M Herr, Nisha M Nair, Theresa Hahn, Chelsea Peterson, Jens Hillengass
Journal of the Neurological Sciences. 2026-03-15 - Analysis of epidemiologic factors and treatment effects on immunophenotypes in hematologic malignancy patients.Theresa Hahn, Megan M Herr, Paul K Wallace, Yali Zhang, Shernan Holtan
Leukemia & Lymphoma. 2026-02-01 - Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.Shernan G Holtan, Punita Grover, Kelly Walton, Najla El Jurdi, Victoria Quinones
Blood Advances. 2026-01-27
Journal Articles
- Amphiregulin in Intestinal Acute Graft-Versus-Host Disease: A Possible Diagnostic and Prognostic AidBrittney Schultz, Bruce R Blazar, Daniel J Weisdorf, Shernan G Holtan, Alexander Khoruts, Armin Rashidi, Margaret L MacMillan, Khalid Amin, Byron P Vaughn, Nature
- Phase I Trial of ALT-803, a Novel Recombinant Interleukin-15 Complex, in Patients with Advanced Solid TumorsJeffrey S Miller, Shernan G Holtan, Sylvia M Lee, Chihiro Morishima, Ann W Silk, Clinical Cancer Research
- Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in MelanomaEnninga EAL, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, Markovic SN, Mayo Clinic Proceedings, 1/1/2014
Abstracts/Posters
- Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationShernan Holtan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/2019
- Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)Shernan Holtan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Prognostic Impact of Follistatin in Acute Graft-Versus-Host Disease: Results from BMT CTN 0302 and 0802Holtan, SG., Michael R. Verneris, Kirk R Schultz, Laura F. Newell, Gabrielle Meyers, Fiona He, Todd E. DeFor, Margaret L. MacMillan, Biology of Blood and Marrow Transplant, 1/1/2015
Lectures
- Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Imm...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Roswell Park Experts Share Latest Hematology Research at 67th ASH Annual MeetingNovember 6th, 2025- Roswell Park’s Stem Cell Transplant Program Recognized by Optum as Center of ExcellenceJuly 16th, 2025
- Tandem 2025: Roswell Park Team Creates Predictive Model to Inform Care of Lymphoma PatientsFebruary 3rd, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
